L-丙氨酸对硝基苯胺 | 26432-41-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-丙氨酸对硝基苯胺
• 英文名称: alanine p-nitroanilide
• 英文别名: Ala-pNA；alanine-(4-nitro-anilide)；Alanin-(4-nitro-anilid)；Alanin-<4-nitro-anilid>；Ala-4-nitroanilid；2-Amino-N-(4-nitrophenyl)propanamide
• CAS: 26432-41-7
• 化学式: C₉H₁₁N₃O₃
• mdl: MFCD07434828
• 分子量: 209.205
• InChiKey: PXFUDSMGEYRNNC-UHFFFAOYSA-N

物化性质

• 沸点：
  443.4±30.0 °C(Predicted)
• 密度：
  1.350±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  L-丙氨酸对硝基苯胺 在 Rhodococcus erythropolis TA₃₇ acylamidase 作用下， 反应 0.33h， 生成 4-硝基苯胺 、 DL-丙氨酸
  参考文献：
  名称：

  A new acylamidase from Rhodococcus erythropolis TA37 can hydrolyze N-substituted amides

  摘要：

  A new acylamidase was isolated from Rhodococcus erythropolis TA37 and characterized. N-Substituted acrylamides (isopropyl acrylamide, N,N-dimethyl-aminopropyl acrylamide, and methylene-bis-acrylamide), acid para-nitroanilides (4'-nitroacetanilide, Gly-pNA, Ala-pNA, Leu-pNA), and N-acetyl derivatives of glycine, alanine, and leucine are good substrates for this enzyme. Aliphatic amides (acetamide, acrylamide, isobutyramide, n-butyramide, and valeramide) are also used as substrates but with less efficiency. The enzyme subunit mass by SDS-PAGE is 55 kDa. Maximal activity is exhibited at pH 7-8 and 55A degrees C. The enzyme is stable for 15 h at 22A degrees C and for 0.5 h at 45A degrees C. The Michaelis constant (K (m)) is 0.25 mM with Gly-pNA and 0.55 mM with Ala-pNA. The acylamidase activity is suppressed by inhibitors of serine proteases (phenylmethylsulfonyl fluoride and diisopropyl fluorophosphate) but is not suppressed by inhibitors of aliphatic amidases (acetaldehyde and nitrophenyl disulfides). The N-terminal amino acid sequence of the acylamidase is highly homologous to those of two putative amidases detected from sequenced R. erythropolis genomes. It is suggested that the acylamidase together with the detected homologs forms a new class within the amidase signature family.

  DOI：

  10.1134/s0006297910080080
• 作为产物：
  描述：

  N,N-phthaloyl-DL-alanine-(4-nitro-anilide) 在 甲醇 、 一水合肼 作用下， 生成 L-丙氨酸对硝基苯胺
  参考文献：
  名称：

  Safonowa; Sergiewskaja, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 3391,3394;engl.Ausg.S.3353,3356

  摘要：

  DOI：

文献信息

• Diamine derivatives as inhibitors of leukotriene A4 hydrolase
  申请人：Arnaiz Damian

  公开号：US20070155726A1

  公开（公告）日：2007-07-05

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.

  这项发明涉及式(I)的化合物： 其中r、q、R、R2、R3、R4、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8和R9如本文所述，可以是单一立体异构体或立体异构体混合物，或其药学上可接受的盐、溶剂合物、包合物、多型体、铵离子、N-氧化物或其前药；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病中有用。还公开了包括该发明化合物的药物组合物以及制备该发明化合物的方法。
• Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity
  作者：Dražen Pavlović、Scott Kimmins、Stjepan Mutak

  DOI：10.1016/j.ejmech.2016.09.022

  日期：2017.1

  A novel series of 6-O-substituted 8a-aza-8a-homoerythromycin A 3-O-acylides has been discovered with potent activity against key respiratory pathogens, including those inducibly and constitutively resistant to erythromycin. The best compounds in this series 15na and 15nd showed activity comparable to telithromycin, especially against Haemophilus influenzae and constitutively MLSB-resistant strains

  已经发现了一系列新颖的6 - O-取代的8a-氮杂-8a-同型红霉素A 3- O-酰化物，其对关键的呼吸道病原体具有有效的活性，所述病原体包括对红霉素具有诱导性和组成型抗性的病原体。该系列15na和15nd中最好的化合物显示出与telithromycin相当的活性，尤其是对流感嗜血杆菌和构成性MLS B耐药的肺炎链球菌和化脓性链球菌菌株。此外，15na表现出许多类似药物的特性，包括有利的药代动力学特性和体内功效。例如，15na表现出良好的口服生物利用度（平均F = 42％），并且在体内对红霉素易感性肺炎链球菌的疗效优于telithromycin（1）。因此，15na具有进一步开发这种新型大环内酯类抗生素的巨大潜力。
• Amide inhibitors of leukotriene A4 hydrolase
  申请人：Chen Ming

  公开号：US20070155727A1

  公开（公告）日：2007-07-05

  This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4a , R 4b , R 4c , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , R 9 and R 10 are described herein, or pharmaceutically acceptable salts, solvates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and which are therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of using and preparing the compounds of the invention are also disclosed.

  本发明涉及的化合物的化学式为（I）：其中r、q、R、R2、R3、R4a、R4b、R4c、R5a、R5b、R5c、R6a、R6b、R6c、R7、R8、R9和R10如本文所述，或其药学上可接受的盐、溶剂化合物、多晶形、铵离子、N-氧化物或其前药；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病方面具有用途。本发明还涉及包含所述化合物的药物组合物以及使用和制备所述化合物的方法。
• PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE
  申请人：Celtaxsys, Inc.

  公开号：US20180162804A1

  公开（公告）日：2018-06-14

  This present disclosure is directed to compounds of formula (I): where R 1a , R 1b , R 1c , R 1d , R 1e , R 3 , R 4a , R 4b , R 4c , R 4d , R 6 , R 7 , and R 8 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.

  本公开涉及化合物的化学式（I）： 其中R1a、R1b、R1c、R1d、R1e、R3、R4a、R4b、R4c、R4d、R6、R7和R8如本文所述，作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐、溶剂合物、包合物、多型体、铵离子、N-氧化物或其前药；这些化合物是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病中有用。还提供了包括所述化合物的药物组合物以及制备所述化合物的方法。
• MONAMINE AND MONOAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE
  申请人：Celtaxsys, Inc.

  公开号：US20180162802A1

  公开（公告）日：2018-06-14

  This present disclosure is directed to compounds of formula (I): where r, q, R 1a , R 1b , R 1c , R 1d , R 1e , R 2 , R 3 , R 4a , R 5a , R 5b , R 6a , R 6b , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.

  本公开涉及的化合物具有以下式（I）：其中r，q，R1a，R1b，R1c，R1d，R1e，R2，R3，R4a，R5a，R5b，R6a，R6b，R8和R9如本文所述，作为单一立体异构体或立体异构体混合物，或其药学上可接受的盐，溶剂化合物，包合物，多晶体，铵离子，N-氧化物或其前药；它们是白三烯A4水解酶抑制剂，因此在治疗炎症性疾病方面有用。还提供了包括所述化合物的制药组合物以及制备所述化合物的方法。